US and Indian Pharmacopeias Collaborate on Drug Quality
The two pharmacopeias signed a Memorandum of Understanding as recognition of their collaboration for developing international science-based standards.
The US Pharmacopeial Convention (USP) announced on March 17, 2017 that it had signed a Memorandum of Understanding (MOU) with the Indian Pharmacopoeia Commission (IPC) in recognition of the two pharmacopeias’ collaboration in identifying and developing science-based standards. The two organizations have committed to working together to increase awareness of the importance of quality and safety of medications and safeguard the quality of and access to the drug supply chain.
USP and IPC have collaborated on projects in the past, and USP CEO Dr. Ronald T. Piervincenzi stated, in a press release, that he felt the MOU would be “a significant step forward in how two standard setting bodies can work together to improve global health through quality standards … Our collaboration will amplify the global public health impact of both organizations by leveraging our mutual scientific resources to advance international standards.”
Source: USP
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
